Nano-X Imaging (NNOX) announced that its U.S.-based subsidiary, Nanox Impact, has signed a distribution agreement with Radiology Oncology Systems to distribute its Nanox.ARC systems across the United States. Under the terms of the agreement, Radiology Oncology Systems will support the commercial rollout of the Nanox.ARC, an FDA-cleared, multisource digital tomosynthesis system. “We continue to systematically expand our U.S. commercial footprint through targeted distribution agreements,” said Erez Meltzer, CEO and acting chairman of Nanox. “Radiology Oncology Systems adds another experienced partner to our growing U.S. network, bringing specialized expertise in oncology and diagnostic imaging that complements our existing channel partners and supports measured deployment and continued commercial execution.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NNOX:
- Nano-X Imaging price target lowered to $5 from $7 at Alliance Global
- Nano-X Imaging Balances Growth Hopes With Deepening Losses
- Midday Fly By: QXO to acquire TopBuild, Lilly to buy Kelonia
- Nano-X Imaging reports Q1 adjusted EPS (17c), consensus (15c)
- Nano-X Imaging still sees FY26 revenue $35M, cosnensus $31.58M
